Cargando…

PB2529: RENAL FUNCTIONS EVOLUTION OF 6 SCD PATIENTS TREATED BY L-GLUTAMINE PHARMACEUTICAL GRADE FOR 30 MONTHS: A REAL-WORLD STUDY.

Detalles Bibliográficos
Autores principales:	Yassin, Mohamed, Elenga, Narcisse
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429163/ http://dx.doi.org/10.1097/01.HS9.0000976816.43525.2d

Ejemplares similares

PB2214: SCD POPULATION SURVEY IN ALBANIA, A PROSPECTIVE NON-INTERVENTIONAL MULTI-CENTER STUDY EVALUATING DISEASE AND PATIENTS CHARACTERISTICS OF SICKLE CELL DISEASE IN ALBANIAN SCD POPULATION
por: Cili, A., et al.
Publicado: (2022)

PB2506: EVIDENCE OF SPLEEN STIFFNESS PROGRESSION BY TRANSIENT ELASTOGRAPHY IN SCD PATIENTS: RESULTS FROM AN EXPLORATORY STUDY
por: Piolatto, Andrea, et al.
Publicado: (2023)

PB2606: REAL-WORLD EXPERIENCE OF HETROMBOPAG IN RELAPSE AND REFRACTORY IMMUNE THROMBOCYTOPENIA
por: Feng, Yimei, et al.
Publicado: (2023)

PB2610: EPIDEMIOLOGY AND TREATMENT OF ITP: A SINGLE CENTRE, REAL-WORLD EXPERIENCE
por: Patel, Priya, et al.
Publicado: (2023)

PB1896: ACUTE MYELOID LEUKEMIA (AML): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

PB1950: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

PB1734: SURVIVAL OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN ECUADOR. AN ANALYSIS OF THE REAL WORLD
por: Sabando, Brenner, et al.
Publicado: (2023)

PB2335: BURDEN OF HOSPITALIZATION, COSTS AND CO-MORBIDITIES IN MEDICAID PATIENTS WITH SICKLE CELL DISEASE (SCD): ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE
por: Aggarwal, S., et al.
Publicado: (2022)

PB2028: TREATING MULTIPLE MYELOMA IN A RESOURCE-LIMITED SETTING: REAL-WORLD OUTCOMES
por: Martinez, G., et al.
Publicado: (2022)

PB2274: REAL-WORLD OUTCOME OF FOLLICULAR LYMPHOMA IN TAIWAN: A MULTICENTER REGISTRY STUDY
por: Ko, Bor-Sheng, et al.
Publicado: (2023)

PB2105: LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA: A RETROSPECTIVE, NATIONWIDE, REAL-WORLD STUDY
por: Harsløf, Mads, et al.
Publicado: (2023)

PB1922: THE FIRST REPORT OF REAL-WORLD OUTCOMES OF ZANUBRUTINIB MONOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Luo, Jing, et al.
Publicado: (2023)

PB2001: PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES- A SWEDISH RETROSPECTIVE REAL-WORLD STUDY
por: Schain, Frida, et al.
Publicado: (2023)

PB2003: REAL-WORLD TREATMENT PATTERNS OF PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)
por: Komrokji, Rami S., et al.
Publicado: (2023)

PB2003: REAL-WORLD DURATION OF USE AND DOSING FREQUENCY OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA IN THE U.S.
por: Fonseca, R., et al.
Publicado: (2022)

PB2510: CHARACTERISATION OF SICKLE CELL DISEASE PATIENTS: A PORTUGUESE REAL-WORLD STUDY (ASCEND)
por: Deveza, Maria Manuel, et al.
Publicado: (2023)

PB2399: BRENTUXIMAB VEDOTIN IN TREATING CHINESE PATIENTS WITH LYMPHOMA:A MULTICENTER,REAL-WORLD STUDY
por: Zhang, Xudong, et al.
Publicado: (2023)

PB2643: EFFICACY OF REDUCED-DOSE EMICIZUMAB IN HEMOPHILIA A WITH INHIBITORS: REAL WORLD EXPERIENCE IN MALAYSIA
por: Tang, Andy Sing Ong, et al.
Publicado: (2023)

P115: REAL-WORLD DATA ON THE EFFICACY OF PHARMACEUTICAL-GRADE L-GLUTAMINE IN PREVENTING SICKLE CELL DISEASE-RELATED ACUTE COMPLICATIONS AND HEMOLYSIS IN PEDIATRIC AND ADULT PATIENTS.
por: Elenga, N, et al.
Publicado: (2022)

P1503: REAL WORLD DATA ON EFFICACY OF PHARMACEUTICAL-GRADE L-GLUTAMINE IN PREVENTING SICKLE CELL DISEASE-RELATED ACUTE COMPLICATIONS AND HEMOLYSIS IN PEDIATRIC AND ADULT PATIENTS.
por: Elenga, N., et al.
Publicado: (2022)

PB1924: ARE WE TAKING ADVANTAGE OF THERAPEUTIC OPTIONS IN MYELODYSPLASTIC SYNDROME?-REAL WORLD DATA FROM HUNGARY
por: Miltényi, Z., et al.
Publicado: (2022)

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2023)

PB1935: CARDIOTOXICITY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITORS: A REVIEW OF REAL-WORLD OBSERVATIONAL EVIDENCE
por: Balijepalli, Chakrapani, et al.
Publicado: (2023)

PB2574: HEMOPHAGOCYTIC SYNDROME IN ADULTS - REAL-WORLD DATA ON MORTALITY FROM A TERTIARY REFERENCE CENTER
por: Wojtovicova, Tatiana, et al.
Publicado: (2023)

PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE
por: Hultcrantz, Malin, et al.
Publicado: (2023)

PB2360: HIV-ASSOCIATED BURKITT LYMPHOMA IN THE COMBINATION ANTIRETROVIRAL THERAPY ERA: REAL-WORLD OUTCOMES AND PROGNOSTICATION
por: Wang, Chaoyu, et al.
Publicado: (2023)

PB2457: RUXOLITINIB AS TREATMENT IN PATIENTS WITH ACUTE AND CRONIC GRAFT-VERSUS-HOST DISEASE. REAL WORLD EVIDENCE
por: José Jiménez Nájar, Francisco, et al.
Publicado: (2023)

PB1731: INOTUZUMAB OZOGAMICIN IN LYMPHOID B-CELL MALIGNANCY：A SINGLE CENTER ANALYSIS IN THE REAL WORLD
por: LV, Mengnan, et al.
Publicado: (2023)

PB1886: REAL WORLD EXPERIENCE OF VENETOCLAX-AZACYTIDINE COMBINATION IN FRAIL ELDERLY PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY
por: Rahimi, Muhammad Naim Bin Che, et al.
Publicado: (2023)

PB2057: REAL -WORLD OVERALL SURVIVAL OF MYELOFIBROSIS PATIENTS ON RUXOLITINIB – A 6 YEAR ANALYSIS IN ALBANIAN POPULATION
por: Perolla, A., et al.
Publicado: (2022)

PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Krishnan, A., et al.
Publicado: (2022)

PB2027: PROGNOSTICATION IN THE EVERYDAY MYELOMA CLINIC. A SYSTEMATIC REVIEW OF PROGNOSTIC MODELS VALIDATED IN REAL WORLD POPULATIONS
por: Redder, L., et al.
Publicado: (2022)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

PB2217: REAL-WORLD RESEARCH OF CLINICAL AND HEMATOLOGIC NEOPLASMS RELATED GENETIC MUTATIONS IN 275 POLYCYTHEMIA VERA PATIENTS
por: Zhang, Lan, et al.
Publicado: (2023)

Real-World data on efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients
por: Elenga, Narcisse, et al.
Publicado: (2022)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS
por: Duell, J., et al.
Publicado: (2022)

PB1941: PRELIMINARY EXPLORATION OF PROLONGED USE OF ELTROMBOPAG IN PATIENTS WITH NAÏVE SEVERE APLASTIC ANEMIA IN THE REAL WORLD: DURATION AND EFFICACY
por: Li, R., et al.
Publicado: (2022)

PB2591: REAL WORLD DATA OF THE MANAGEMENT (TREATMENT AND PREVENTION OF COVID-19 DISEASE) IN PATIENTS WITH HEMATOLOGICAL DISEASES DURING THE PANDEMIC
por: Mparmpouti, Aikaterini, et al.
Publicado: (2023)

PB2026: ROLE OF MOLECULAR PROFILING IN MYELODYSPLASTIC SYNDROME IN REAL-WORLD - A NEW APPROACH IN MYELODYSPLASTIC SYNDROME’S RISK STRATIFICATION?
por: Silva, Duarte Pacheco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6cmc46sk60hdongluacflunhen